| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Richard A Bond | |
| Sergio Parra | |||
| P433 | issue | 2 | |
| P304 | page(s) | 146-150 | |
| P577 | publication date | 2007-02-05 | |
| P1433 | published in | Current Opinion in Pharmacology | Q3007702 |
| P1476 | title | Inverse agonism: from curiosity to accepted dogma, but is it clinically relevant? | |
| P478 | volume | 7 |
| Q34788441 | Agnostic about in vivo inverse agonism of agouti-related peptide |
| Q41250110 | Atypical antipsychotics and inverse agonism at 5-HT2 receptors |
| Q24646260 | Beta2-adrenoceptor signaling is required for the development of an asthma phenotype in a murine model |
| Q42480115 | Chemoattraction to lysophosphatidic acid does not require a change in membrane potential inTetrahymena thermophila |
| Q33792699 | Clinical implications of the intrinsic efficacy of beta-adrenoceptor drugs in asthma: full, partial and inverse agonism |
| Q42525438 | Constitutive activity of the cannabinoid CB1 receptor regulates the function of co-expressed Mu opioid receptors |
| Q37416428 | Discriminative stimulus effects of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM), ketanserin, and (R)-(+)-{alpha}-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-pipidinemethanol (MDL100907) in rats |
| Q35163044 | For the love of paradox: from neurobiology to pharmacology |
| Q37778511 | Inverse Agonism at Serotonin and Cannabinoid Receptors |
| Q34770179 | Inverse agonist and pharmacochaperone properties of MK-0524 on the prostanoid DP1 receptor |
| Q38801257 | Ligand-Independent Adenosine A2B Receptor Constitutive Activity as a Promoter of Prostate Cancer Cell Proliferation |
| Q58798205 | Making Sense of Pharmacology: Inverse Agonism and Functional Selectivity |
| Q36259485 | Maturational alterations in constitutive activity of medial prefrontal cortex kappa-opioid receptors in Wistar rats |
| Q39635741 | Measurement of Inverse Agonism in β-Adrenoceptors |
| Q30371695 | Modeling the effects of β1-adrenergic receptor blockers and polymorphisms on cardiac myocyte Ca2+ handling. |
| Q36859581 | Noncompetitive antagonism and inverse agonism as mechanism of action of nonpeptidergic antagonists at primate and rodent CXCR3 chemokine receptors |
| Q41906281 | Signalling profile differences: paliperidone versus risperidone |
| Q37550543 | Therapeutic management of allergic diseases. |
| Q36703892 | β2-Adrenoceptor agonists are required for development of the asthma phenotype in a murine model |
| Q51031520 | γ-Aminobutyric Acid Type A (GABAA) Receptor Subtype Inverse Agonists as Therapeutic Agents in Cognition |
Search more.